Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis

Martin R. Turner, Michael G Benatar

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.

Original languageEnglish
Pages (from-to)14-18
Number of pages5
JournalMuscle and Nerve
Volume51
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Amyotrophic Lateral Sclerosis
Biomarkers
Neurodegenerative Diseases
Therapeutics

Keywords

  • Biomarker
  • Motor neuron disease
  • Neurochemistry
  • Neuroimaging
  • Trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. / Turner, Martin R.; Benatar, Michael G.

In: Muscle and Nerve, Vol. 51, No. 1, 01.01.2014, p. 14-18.

Research output: Contribution to journalArticle

@article{ccc70c483c6e429da44191f3da2efd4c,
title = "Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis",
abstract = "Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.",
keywords = "Biomarker, Motor neuron disease, Neurochemistry, Neuroimaging, Trial",
author = "Turner, {Martin R.} and Benatar, {Michael G}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/mus.24470",
language = "English",
volume = "51",
pages = "14--18",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis

AU - Turner, Martin R.

AU - Benatar, Michael G

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.

AB - Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.

KW - Biomarker

KW - Motor neuron disease

KW - Neurochemistry

KW - Neuroimaging

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=84916912474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916912474&partnerID=8YFLogxK

U2 - 10.1002/mus.24470

DO - 10.1002/mus.24470

M3 - Article

C2 - 25288265

AN - SCOPUS:84916912474

VL - 51

SP - 14

EP - 18

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -